Showing results (211-220 of 317) with videos related to

Sort By:
Pageof 32
Tumori|December 31, 1991
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patientsS Spinazzé, S Viviani, P Bidoli, et al.
Cancer Research|September 1, 1990
In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumorsL Rivoltini, C Gambacorti-Passerini, M Squadrelli-Saraceno, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 30, 1998
Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanomaC Clemente, S Rao, R Lupetti, et al.
The Journal of Clinical Investigation|July 1, 1991
Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m geneM Maio, M Altomonte, R Tatake, et al.
Melanoma Research|November 1, 1992
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot studyF Belli, F Arienti, L Rivoltini, et al.
Cancer Research|January 4, 1998
Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursorsR Mortarini, A Anichini, M Di Nicola, et al.
Cancer Research|June 11, 1998
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35)D J Loftus, P Squarcina, M B Nielsen, et al.
Experimental Hematology|December 1, 1995
Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapyS Siena, M Di Nicola, M Bregni, et al.
Cancer Research|September 15, 1989
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activationC Gambacorti-Passerini, L Rivoltini, M Radrizzani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1996
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patientsS Dermime, C Bertazzoli, E Marchesi, et al.
Pageof 32